Glucotrack Aims to Revolutionize Painful Diabetic Neuropathy Treatment with Novel Technology

NEW YORK, NY – October 29, 2025 – Glucotrack, Inc. (Nasdaq: GCTK) is making a bold move into the expanding market for painful diabetic neuropathy (PDN) treatment with its unique approach of integrating continuous glucose monitoring (CGM) with spinal cord stimulation (SCS). The company recently appointed Usman Latif, MD, MBA, a leading pain management specialist, to its clinical advisory team, signaling a strong commitment to this novel strategy.

Addressing a Significant Unmet Need

Painful Diabetic Neuropathy affects over 7 million Americans – roughly 20% of the 38 million people living with diabetes. This debilitating condition causes pain, numbness, and weakness in the feet and legs, significantly impacting quality of life. Current treatments range from medications offering limited relief to invasive procedures like spinal cord stimulation. However, many patients continue to struggle with persistent pain, highlighting the need for more effective and holistic solutions.

“For patients with PDN, managing their condition often involves multiple devices and disjointed streams of information,” notes one expert in the field. “The potential to simplify this process and provide a more integrated approach is appealing.” While SCS has proven effective for many, the integration of continuous glucose monitoring represents a potentially significant advancement. It’s hypothesized that a more comprehensive understanding of a patient’s metabolic state, coupled with pain management, could unlock even better outcomes.

Glucotrack’s Innovative Approach

Glucotrack’s strategy is to develop technology that combines long-term implantable CGM systems with spinal cord stimulation. The company believes that by directly monitoring glucose levels in the epidural space, they can provide physicians with real-time data to optimize pain management and potentially improve glycemic control. This innovative approach differs from current PDN treatments, which primarily focus on pain relief without addressing the underlying metabolic factors.

“The vision is to create a closed-loop system where glucose monitoring informs pain management and vice versa,” explains a source familiar with the company’s technology. “This could lead to more personalized and effective treatment plans.” The company recently completed a long-term preclinical study demonstrating the feasibility and safety of epidural glucose monitoring. This study, which involved implanting a sensor in the epidural space and tracking glucose levels, yielded promising results and supports the potential for human clinical trials.

Navigating a Competitive Landscape and Financial Challenges

The SCS market for PDN is already crowded, with established players like Nevro, Medtronic, Abbott, and Boston Scientific vying for market share. These companies have all received FDA approval for their SCS devices to treat PDN. However, none are currently pursuing the direct integration of continuous glucose monitoring into SCS leads in the same way as Glucotrack.

“While SCS is effective at masking pain, it doesn’t address the underlying metabolic issues,” one physician specializing in chronic pain states. “Glucotrack’s approach could potentially address both the pain and the metabolic dysfunction, which could lead to better long-term outcomes.”

Despite the promising technology, Glucotrack faces significant financial challenges. The company has reported net losses in recent quarters and is reliant on external financing to fund its operations. The company has recently raised capital through equity sales and a promissory note, but management acknowledges that conditions raise substantial doubt about its ability to continue as a going concern. They estimate a need for approximately $15 million to fund operations over the next twelve months. Successfully navigating this financial landscape will be crucial for Glucotrack to bring its innovative technology to market.

The Path Forward: Clinical Trials and Regulatory Approval

Glucotrack is now preparing to initiate human clinical trials for its long-term implantable CBGM system and is seeking FDA approval for an Investigational Device Exemption (IDE). The company anticipates beginning long-term clinical studies in Australia in the coming months and expects to submit an IDE to the FDA by the end of the year.

“The next few years will be critical for Glucotrack,” says an industry analyst. “Successfully completing clinical trials and obtaining regulatory approval will be key to unlocking the potential of this technology and establishing a foothold in the PDN market.”

If Glucotrack can demonstrate the safety and efficacy of its integrated glucose monitoring and SCS system, it could revolutionize the treatment of painful diabetic neuropathy and improve the lives of millions of patients. The company’s appointment of a leading pain management expert to its clinical advisory team signals a commitment to this ambitious goal.